326 related articles for article (PubMed ID: 31101647)
21. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
22. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
24. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
25. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
26. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
27. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland.
Barbier M; Durno N; Bennison C; Örtli M; Knapp C; Schwenkglenks M
Eur J Health Econ; 2022 Jul; 23(5):837-846. PubMed ID: 34757508
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
31. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Mato AR; Sharman JP; Biondo JML; Wu M; Mun Y; Kim SY; Humphrey K; Boyer M; Zhu Q; Seymour JF
Haematologica; 2022 Jan; 107(1):134-142. PubMed ID: 33327712
[TBL] [Abstract][Full Text] [Related]
32. Frontline treatment in CLL: the case for time-limited treatment.
Lévy V; Delmer A; Cymbalista F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
34. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R; Gibiansky L; Lu T; Li X; Lu D; Li C; Girish S; Wang J; Boyer M; Shankar N; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Leuk Lymphoma; 2020 Jan; 61(1):56-65. PubMed ID: 31549889
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
Blair HA
Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR
Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
38. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
39. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]